Azenta, Inc.

Azenta, Inc. is a leading global provider of life sciences solutions, dedicated to accelerating breakthroughs and therapies for its customers. The company's mission is to enable life science organizations worldwide to bring impactful discoveries and treatments to market faster. Headquartered in Burlington, Massachusetts, U.S., Azenta operates as a pure-play life sciences company, having divested its semiconductor automation business in 2022.

Azenta's core offerings are structured around two main segments: Life Sciences Products and Life Sciences Services, also referred to as Sample Management Solutions and Multiomics. The company provides a comprehensive suite of cold-chain sample management solutions, including automated cold storage, cryogenic systems, consumables, instruments, and sample repository services. Its Multiomics services encompass genomic analysis, gene sequencing, and gene synthesis, often delivered under the GENEWIZ brand. These products and services cater to critical needs in drug development, clinical research, and advanced cell therapies for pharmaceutical, biotech, academic, and healthcare institutions globally.

John P. Marotta assumed the role of President and CEO of Azenta, Inc. in September 2024, bringing extensive experience in the life sciences sector. Recent corporate activities include the publication of its 2025 Environmental, Social, and Governance (ESG) Report and the reporting of its second-quarter fiscal 2026 earnings in May 2026. The company also completed the strategic acquisition of UK Biocentre Limited in March 2026 to expand its biorepository capabilities and announced the definitive agreement for the sale of its B Medical Systems business in December 2025.